Otsuka America Pharmaceutical, Inc.

33 articles with Otsuka America Pharmaceutical, Inc.

• For the 2nd Year in a Row, Otsuka Convenes National Forum on Advancing Mental Health Policy

  10/17/2019

  Top Experts, Lawmakers and Advocates Come Together to Discuss Policy Solutions to Support Growing Number of Americans Living with Mental Illness

• 

  Clinical Catch-up from Last Week: June 1-June 7

  6/10/2019

  Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.

• Otsuka Announces First Collaboration Agreement to Bring the ABILIFY MYCITE® System to the US Market

  8/30/2018

  The ABILIFY MYCITE System, the first drug-device combination product to be approved by FDA to track drug ingestion, will be integrated into Magellan Health’s mental health provider network

• Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

  7/23/2018

  Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.

• 

  The Dementia Discovery Fund Raises $350 Million from Investors AARP, NFL and Others

  6/26/2018

  The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.

• The Digital Therapeutics Alliance Announces New Members

  5/8/2018

  The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership

• 

  Digital Health Movement Continues to Grow, as Do Concerns Over Privacy

  5/2/2018

  Getting patients to adhere to long-term treatments can be difficult. There are a number of new therapies that will monitor whether or not patients are sticking to their regimen.

• Avella Selected by Otsuka to distribute JYNARQUE

  4/27/2018

  Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD).

• Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care

  2/28/2018

  Held at Elevate by Psych Congress, a gathering of up-and-coming leaders in mental health care, the event featured some of the most groundbreaking technologies in the mental health marketplace.

• Otsuka America Pharma's Abilify Can Cause Urges to Gamble, Eat, Shop, Have Sex: FDA

  5/5/2016

• Otsuka America Pharmaceutical, Inc. Release: Results Of New Survey Show Nearly Two Thirds Of Surveyed Adults With Major Depressive Disorder (MDD) Who Report Taking Their Medication As Prescribed Still Experience Symptoms At Least Weekly

  2/11/2016

• Otsuka America Pharmaceutical, Inc. Release: FDA Approves Deltoid Injection Site For Abilify Maintena (Aripiprazole) For Extended-Release Injectable Suspension In The Treatment Of Schizophrenia

  7/30/2015

• Otsuka America Pharmaceutical, Inc. And Lundbeck Inc. To Present Data On Investigational Compound Brexpiprazole In Schizophrenia And Major Depressive Disorder At American Psychiatric Association Annual Meeting

  5/13/2015

• H. Lundbeck A/S and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry

  4/17/2015

• Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension

  12/15/2014

• Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia

  11/3/2014

• European Medicines Agency Accepts Otsuka America Pharmaceutical, Inc.'s Marketing Authorisation Application (MAA) For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  12/27/2013

• Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. Release: Four-Year Data From Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML

  12/10/2013

• Almac Group Receives Appreciation Award From Otsuka America Pharmaceutical, Inc.

  7/31/2013

• Almac Group Receives Appreciation Award From Otsuka America Pharmaceutical, Inc.

  7/31/2013